{"schema_version":"1","generated_at":"2026-11-21T16:08:40.514Z","data_as_of":null,"url":"https://www.findmykol.com/kol/katherine-moxley","json_url":"https://www.findmykol.com/kol/katherine-moxley/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"katherine-moxley","name":"Katherine Moxley","credential":"MD","specialty":"Gynecologic Oncology","specialty_raw":"Gynecologic Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Oklahoma Cancer Specialists and Research Institute","institution_url":"https://www.findmykol.com/institution/oklahoma-cancer-specialists-and-research-institute","city":"Tulsa","state":"OK","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Katherine Moxley is an Oncology physician affiliated with Oklahoma Cancer Specialists and Research Institute. OpenAlex indexes 145 publications with 38,273 citations (h-index 55). By OpenAlex citation count, this profile ranks in the top 5% of Gynecologic Oncology profiles in the FindMyKOL directory.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":145,"cited_by_count":38273,"h_index":55,"latest_activity_year":2025,"citation_standing":{"top_percent":5,"cohort":"Gynecologic Oncology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"payments":{"company_count":11,"program_years":{"first":2021,"last":null},"rows_total":27,"shown":3,"withheld":24,"rows":[{"payer":"GlaxoSmithKline, LLC.","program_year":2025,"amount_usd":17324.98,"payment_count":12},{"payer":"INTUITIVE SURGICAL, INC.","program_year":2025,"amount_usd":6182.33,"payment_count":15},{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":725,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":8,"areas_shown":3,"areas":[{"area":"Blood & clotting","share_pct":69.4,"classes_total":1,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":69.4,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":15}]},{"area":"Metabolism & gastrointestinal","share_pct":24.2,"classes_total":2,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":13.8,"drugs":[{"name":"Granisetron","share_pct":98.6},{"name":"Ondansetron Hcl","share_pct":1.4}],"max_beneficiaries":20},{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":10.4,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":12}]},{"area":"Sensory organs","share_pct":5.2,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"administered","share_pct":5.2,"drugs":[{"name":"Dexamethasone sodium phosphate","share_pct":100}],"max_beneficiaries":41}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":99.6,"facility_pct":0.4},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2018,"last":2020},"rows_total":3,"shown":3,"withheld":0,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"P20GM103639","title":"Exosomes in Predicting Response to Chemotherapy in Metastatic Endometrial Carcinoma","fiscal_year":2020,"amount_usd":"216227","organization":"UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR","source_url":"https://reporter.nih.gov/quickSearch/P20GM103639"},{"project":"P20GM103639","title":"Exosomes in Predicting Response to Chemotherapy in Metastatic Endometrial Carcinoma","fiscal_year":2019,"amount_usd":"216874","organization":"UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR","source_url":"https://reporter.nih.gov/quickSearch/P20GM103639"},{"project":"P20GM103639","title":"Exosomes in Predicting Response to Chemotherapy in Metastatic Endometrial Carcinoma","fiscal_year":2018,"amount_usd":"217500","organization":"UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR","source_url":"https://reporter.nih.gov/quickSearch/P20GM103639"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","year":2023,"journal":"The Lancet","source_url":"https://doi.org/10.1016/s0140-6736(23)02405-4","status":"verified"},{"title":"TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study","year":2022,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.21.02506","status":"verified"},{"title":"Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study","year":2021,"journal":"Gynecologic Oncology","source_url":"https://doi.org/10.1016/j.ygyno.2021.01.025","status":"verified"},{"title":"Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)","year":2020,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-20-0776","status":"verified"},{"title":"The Immune Landscape of Cancer","year":2019,"journal":"Immunity","source_url":"https://doi.org/10.1016/j.immuni.2019.08.004","status":"verified"}],"source":"works"},"similar":[{"name":"Daron Street","slug":"daron-street","institution":"Oklahoma Cancer Specialists and Research Institute","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/daron-street","json_url":"https://www.findmykol.com/kol/daron-street/profile.json"},{"name":"Janelle Pavlis","slug":"janelle-pavlis","institution":"Oklahoma Cancer Specialists and Research Institute","specialty":"Dermatology","url":"https://www.findmykol.com/kol/janelle-pavlis","json_url":"https://www.findmykol.com/kol/janelle-pavlis/profile.json"},{"name":"Paul Zito","slug":"paul-zito","institution":"Oklahoma Cancer Specialists and Research Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/paul-zito","json_url":"https://www.findmykol.com/kol/paul-zito/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":24,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}